BioCompute.ai is the Industrial Operating System for Precision Medicine—delivering sovereign, audit-ready AI infrastructure for multi-omics workflows.

Native integration with intoDNA STRIDE™ enables real-time, quantitative DNA damage/repair analysis (single-molecule resolution)—AstraZeneca-validated (Oct 2025 prostate combo study, published NAR Cancer).

Key differentiators:

• Telemetry Airlock: Zero data exfiltration, air-gapped NVIDIA models
• Evidence Engine: Automated lineage (21 CFR Part 11, IEEE 2791)
• NVIDIA Inception: Preferred H100/H200 acceleration (4-10x speedup)
• Agentic orchestration ready (patent pending)

Seeking strategic design partners for oncology/DDR pipelines, biomarker programs, and translational AI. Limited 2026 Charter Cohort open—early access, co-design, dedicated engineering.

Let's accelerate regulated precision medicine together.

biocompute.ai | #JPM2026